Debruyne et al. [69] conducted a multicenter, randomized study of 1051 patients with BPH. Patients received ER alfuzosin 5 mg twice daily, finasteride 5 mg daily, or both drugs for six months.

The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

Drug treatment of BPH was initially viewed with suspicion by urologists, but has gradually achieved widespread acceptance, with excellent consequences for patients. Urologists had further ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

A breakthrough in prostate cancer treatment has seen a drug shrink tumours in advanced disease ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.